Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

and cash equivalents

$  71,074,807$
5,893,970Accounts receivable, net of allowances

4,505,4115,145,494Inventories

6,874,5997,683,842Other current assets

3,423,5742,315,536Total current assets

85,878,39181,038,842Property and equipment, net

1,198,8051,220,010Intangible assets, net

7,029,1867,427,223Other assets

1,972,2842,367,979Total assets

$  96,078,666$
92,054,054LIABILITIES AND EQUITYCurrent liabilities:Current portion of long-term debt

$
-$
2,666,668Accounts payable

3,280,2892,124,654Other current liabilities

4,172,9424,436,298Total current liabilities

7,453,2319,227,620Revolving line of credit

4,575,9511,825,951Long-term debt, excluding current portion

-2,666,665Other long-term obligations, excluding current portion

592,427618,343Total liabilities

12,621,60914,338,579Commitments and contingenciesEquity:Shareholders' equity:Common stock - no par value; 100,000,000 shares authorized;20,215,910 and 20,338,461 shares issued and outstandingas of September 30, 2011 and December 31, 2010, respectively

71,802,06870,778,874Retained earnings

11,744,9976,998,806Total shareholders' equity

83,547,06577,777,680Noncontrolling interests

(90,008)(62,205)Total equity

83,457,05777,715,475Total liabilities and equity

$  96,078,666$
92,054,054CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Income(Unaudited)Three months ended September 30,Nine months ended September 30,2011201020112010Net revenues

$
3,054,278$
2,190,870$
38,110,946$
33,061,457Costs and expenses:Cost of products sold

1,341,256909,4343,411,3542,632,447Selling and marketing

5,060,5465,692,04816,253,57417,147,683Research and development

1,233,0251,138,9553,269,7462,947,623General and administrative

2,117,6841,806,9756,442,1395,471,012Amortization of
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
2. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
7. Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock
8. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
(Date:8/20/2014)... 2014 /PRNewswire-iReach/ -- A case study from Intel ... school,s bioengineering department and the Intel® Internet of ... Academic Program, UCSD,s research focuses on exploring the ... Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... of Dr. Todd P. Coleman , Associate ...
(Date:8/19/2014)... August 19, 2014 Shimadzu Scientific ... systems, Prominence-i and Nexera-i, adding to the company’s ... excellent functionality, an intuitive operating environment, and full ... more efficient workflow for conventional to ultra-high-speed analysis. ... intuitive and intelligent design so users can begin ...
(Date:8/19/2014)... Jolla, CA (PRWEB) August 19, 2014 ... toll Parkinson’s disease can take on an individual. ... extremities, decreased facial expression, problems swallowing and severe depression. ... to the dying off of dopamine producing neurons of ... themselves from a disease that slowly and progressively gets ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... Vivo Ventures, a venture,capital firm specializing in life ... firm as an Executive in Residence. With his,extensive business ... portfolio companies while enhancing the firm,s presence in,Asia. ... what he will be able to,bring to Vivo," said ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that ... U.K. Phase Ia/Ib combination,REOLYSIN(R)/radiation clinical trial for ... to be presented today at the AACR-NCI-EORTC,International ... in,San Francisco. The conference runs from October ...
... 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... letter of approval from the U.K. Medicines ... Clinical Trial Application (CTA) to begin,a clinical ... with cyclophosphamide, a chemotherapeutic agent as well ...
Cached Biology Technology:Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence 2Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 2Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 3
(Date:8/20/2014)... grows to about 4,000 members, it triggers an important ... a special type of comb used for rearing male ... Department of Neurobiology and Behaviour at Cornell University, led ... of honeybee colonies. The results are published in Springer,s ... , Reproduction isn,t always a honeybee colony,s top ...
(Date:8/20/2014)... 20, 2014  The second annual Biometrics UnPlugged ... Tampa, Florida on September 15, ... Rahman, Director, Technology and Strategy at Samsung, and Philippe ... theme of this year,s event is Mobility at ... "Biometrics UnPlugged: Mobility at the Crossroads of ...
(Date:8/19/2014)... is available in German . ... intermittent energy sources. If a large amount of electricity is ... excess energy will have to be stored during productive periods ... storage capacities are far from adequate for the purpose. Science ... important focus lies on battery systems that used to be ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... A*STAR scientists from the Institute of Molecular and Cell Biology ... 100 years, by constructing stable haploid strains of ... This discovery, jointly made by two teams of scientists led ... Berman of the University of Minnesota, will enable scientists to ...
... Chronicle of Higher Education , the National Institutes ... in the review of grant applications. (Found at: ... professor of biomedical engineering at the Virginia ... Engineering and Sciences , and seven of his ...
... the journal Science , today announces the 53 ... Technology Visualization Challenge, a highly competitive contest jointly sponsored ... magazine is published by the American Association for the ... than 200 entries from 18 countries, including entries from ...
Cached Biology News:A*STAR scientists solve century-old mystery by finding stable haploid strains of Candida albicans 2Virginia Tech adjunct and colleagues refute a study on 'racial bias' report in NIH awards 2Virginia Tech adjunct and colleagues refute a study on 'racial bias' report in NIH awards 3Winners of 10th annual International Science & Technology Visualization Challenge announced 2Winners of 10th annual International Science & Technology Visualization Challenge announced 3
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Request Info...
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
Green Standard is fluorescein....
Biology Products: